Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-119 + metformin
- Development stage
- Unknown
- Lead developer
- PegBio
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
PB-119 + metformin is a combination therapy under investigation for the treatment of type 2 diabetes. PB-119 is a pegylated human glucagon-like peptide 1 (GLP‑1) receptor agonist, designed to improve beta-cell function and insulin resistance. It acts by stimulating the GLP‑1 receptor, leading to enhanced insulin secretion and improved glycemic control. Metformin is an oral antidiabetic agent in the biguanide class that decreases hepatic glucose production, increases peripheral glucose uptake, and improves insulin sensitivity without causing significant hypoglycemia or weight gain. The combination aims to provide superior glycemic control compared to monotherapy, with clinical trials showing significant reductions in HbA1c and fasting/post-prandial blood glucose levels[6][8][3].
- Brand names
- GlucophageFortametGlumetzaRiomet
- Other names
- PEGylated exenatide injection (for PB-119)biguanide (for metformin)
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)GLP1R (GLP-1R)
Beyond the preview
Go deeper on PB-119 + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-119 + metformin.